<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-20T23:16:58Z</responseDate><request verb="GetRecord" identifier="oai:wakespace.lib.wfu.edu:10339/14872" metadataPrefix="dim">https://wakespace.lib.wfu.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:null:10339/14872</identifier><datestamp>2026-09-18T13:41:39Z</datestamp><setSpec>com_10339_14934</setSpec><setSpec>col_10339_38132</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Wilhelm, Ashley</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned" lang="en_US">2010-05-06T16:25:03Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2010-06-18T18:59:38Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available" lang="en_US">2010-05-06T16:25:03Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2010-06-18T18:59:38Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2010-05-06T16:25:03Z</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://wakespace.lib.wfu.edu/handle/10339/14872</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">The goal of this work was to examine the role of apoA-I in atherosclerosis and autoimmunity. We used a mouse model lacking the LDL receptor and the apoA-I gene (LDLr-/-,ApoA-I-/- or DKO). LDLr-/- (SKO) mice were used as controls. When fed a cholesterol-containing diet, DKO mice exhibited cholesterol accumulation in the skin and skin-draining lymph nodes (LNs). The LN total cell number was increased, with expansion of T cell, B cell, dendritic cell (DC) and macrophage populations. Interestingly, DKO LN T cells, B cells and DCs had increased cholesterol compared to controls. DKO LN T cells had increased expression of activation markers and proliferation of CD4+CD44high T cells was increased. Plasma autoantibodies were also increased. We concluded that, in the absence of apoA-I, diet-fed DKO mice develop an autoimmune phenotype. These data suggest that apoA-I can modulate immune cell function by regulating cellular cholesterol balance. This, in turn, prevents LN cell expansion, activation and the progression of atherosclerosis. 
     Regulatory T cells (Treg) were increased in LNs of DKO mice. To determine the direct effects of apoA-I on this cell population and the autoimmune phenotype, mice were fed diet for 6 weeks then apoA-I injections began and continued every 48 hours for an additional 6 weeks. After 12 weeks total on diet, apoA-I-treated DKO mice (DKO+A-I) had reduced LN size and reduced LN cell number compared to DKO mice treated with BSA (DKO+BSA). The skin cholesterol was also massively reduced, with inflammatory cell infiltration in the skin reduced compared to DKO+BSA. The LN Treg population was increased even further compared to DKO+BSA. This increase, however, was different than that seen in DKO+BSA mice because it also resulted in a decrease in cellular activation. These data indicate that apoA-I is effective in improving the Treg response in autoimmune mice, preventing autoimmunity.
     We have identified apoA-I as potential mechanistic link between atherosclerosis and autoimmunity. ApoA-I treatment prevented cholesterol accumulation and improved the Treg response in DKO mice, thus preventing autoimmunity. Therefore, treatment with apoA-I to increase HDL levels may be an important option to consider when devising treatments for both atherosclerosis and autoimmunity.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en_US</dim:field>
   <dim:field mdschema="dc" element="publisher" lang="en_US">Wake Forest University</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Immunology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Pathology</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">The Role of Apolipoprotein A-I in the Modulation of Cholesterol and Immune Homeostasis</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Dissertation</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="accessRights" lang="en_US">Release the entire work immediately for access worldwide.</dim:field>
   <dim:field mdschema="thesis" element="contributor" qualifier="committeeChair" lang="en_US">Thomas, Michael</dim:field>
   <dim:field mdschema="thesis" element="contributor" qualifier="committeeMember" lang="en_US">Sorci-Thomas, Mary</dim:field>
   <dim:field mdschema="thesis" element="contributor" qualifier="committeeMember" lang="en_US">Parks, John</dim:field>
   <dim:field mdschema="thesis" element="contributor" qualifier="committeeMember" lang="en_US">Grayson, Jason</dim:field>
   <dim:field mdschema="thesis" element="contributor" qualifier="committeeMember" lang="en_US">Schwartz, Elizabeth</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline" lang="en_US">Molecular &amp;amp; Cellular Pathobiology</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>